TY - JOUR
T1 - Pathophysiology of ischaemia reperfusion injury
T2 - Central role of the neutrophil
AU - Welbourn, C. R.B.
AU - Goldman, G.
AU - Paterson, I. S.
AU - Valeri, C. R.
AU - Shepro, D.
AU - Hechtman, H. B.
PY - 1991/6
Y1 - 1991/6
N2 - Ischaemia is a common clinical event leading to local and remote injury. Evidence indicates that tissue damage is largely caused by activated neutrophils which accumulate when the tissue is reperfused. If the area of ischaemic tissue is large, neutrophils also sequester in the lungs, inducing non‐cardiogenic pulmonary oedema. Ischaemia reperfusion injury is initiated by production of reactive oxygen species which initially appear responsible for the generation of chemotactic activity for neutrophils. Later, once adherent to endothelium, neutrophils mediate damage by secretion of additional reactive oxygen species as well as proteolytic enzymes, in particular elastase. Therapeutic options for limiting ischaemia reperfusion injury include inhibition of oxygen radical formation, pharmacological prevention of neutrophil activation and chemotaxis, and also the use of monoclonal antibodies which prevent neutrophil‐endothelial adhesion, a prerequisite for injury.
AB - Ischaemia is a common clinical event leading to local and remote injury. Evidence indicates that tissue damage is largely caused by activated neutrophils which accumulate when the tissue is reperfused. If the area of ischaemic tissue is large, neutrophils also sequester in the lungs, inducing non‐cardiogenic pulmonary oedema. Ischaemia reperfusion injury is initiated by production of reactive oxygen species which initially appear responsible for the generation of chemotactic activity for neutrophils. Later, once adherent to endothelium, neutrophils mediate damage by secretion of additional reactive oxygen species as well as proteolytic enzymes, in particular elastase. Therapeutic options for limiting ischaemia reperfusion injury include inhibition of oxygen radical formation, pharmacological prevention of neutrophil activation and chemotaxis, and also the use of monoclonal antibodies which prevent neutrophil‐endothelial adhesion, a prerequisite for injury.
UR - https://www.scopus.com/pages/publications/0025764451
U2 - 10.1002/bjs.1800780607
DO - 10.1002/bjs.1800780607
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:0025764451
SN - 0007-1323
VL - 78
SP - 651
EP - 655
JO - British Journal of Surgery
JF - British Journal of Surgery
IS - 6
ER -